Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study was to evaluate the efficacy (and safety) of antiviral therapy in patients with chronic hepatitis C after liver transplantation. The only approved drugs for treatment of hepatitis C are pegylated interferon and ribavirin.
Condition or disease
Drug: Pegylated interferon and ribavirin
Hepatitis C recurrence after liver transplantation remains the main cause of graft loss after liver transplantation. Several strategies can be used to prevent or treat hepatitis C in the setting of liver transplantation. There are no controlled studies evaluating the efficacy and safety of antiviral treatment (using pegylated interferon and ribavirin) in liver transplant recipients. The main endpoint of this study was: 1) histological outcomes (effect of antiviral treatment on disease progression, i.e. liver fibrosis). The secondary endpoint were 1) Sustained virological response (persistent HCV-RNA clearance) and 2) Safety of pegylated interferon and ribavirin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chronic hepatitis C defined by liver biopsy and presence of HCV-RNA
More than 6 months from liver transplantation
Written inform consent
Severe hepatitis C recurrence (F3-F4 fibrosis stage, cholestatic hepatitis)
Double liver-kidney transplantation
Leucopenia (2000) or thrombocytopenia (40.000)
Anemia (Hemoglobin lower than 10 g/dL)
Renal failure (creatinine > 2 mg/dL)
All contraindications for interferon and ribavirin therapy